Top Page
HBM Holdings Ltd.
(2142)
HBM Holdings Ltd. (2142) vs. iShares MSCI Hong Kong ETF (EWH)
HBM Holdings Ltd. Business Overview & Revenue Model
HBM Holdings Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.06M | 38.10M | 89.50M | 40.66M | 4.31M | 14.11M |
| Gross Profit | 59.33M | 33.61M | 87.47M | 40.53M | 4.17M | 13.66M |
| EBITDA | 32.64M | -2.08M | 31.18M | -117.07M | -130.84M | -290.91M |
| Net Income | 37.21M | 2.78M | 22.80M | -137.27M | -137.88M | -296.54M |
Balance Sheet | ||||||
| Total Assets | 380.47M | 215.01M | 228.48M | 232.12M | 282.36M | 388.74M |
| Cash, Cash Equivalents and Short-Term Investments | 320.69M | 167.22M | 140.72M | 171.71M | 216.30M | 356.95M |
| Total Debt | 64.67M | 61.34M | 66.01M | 90.93M | 19.47M | 1.73M |
| Total Liabilities | 96.89M | 90.96M | 108.85M | 139.62M | 59.45M | 27.73M |
| Stockholders Equity | 282.70M | 124.45M | 119.99M | 92.83M | 223.19M | 361.19M |
Cash Flow | ||||||
| Free Cash Flow | -5.75M | 30.44M | -21.60M | -118.40M | -139.81M | -35.99M |
| Operating Cash Flow | -5.70M | 30.68M | -19.12M | -99.96M | -125.61M | -35.39M |
| Investing Cash Flow | 1.75M | 6.55M | 28.09M | 137.59M | -76.90M | -93.53M |
| Financing Cash Flow | -4.32M | -10.24M | -29.14M | 70.58M | 1.59M | 357.86M |
HBM Holdings Ltd. Technical Analysis
HBM Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$11.53B | 45.14 | 13.34% | ― | 206.58% | ― | |
| ― | HK$10.45B | 54.91 | 6.73% | ― | 23.37% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$11.43B | 17.53 | 35.80% | ― | 59.70% | 239.97% | |
| ― | HK$9.18B | -20.28 | -95.84% | ― | -55.64% | -158.67% | |
| ― | HK$11.52B | -55.06 | -21.42% | ― | 240.05% | -140.09% |
HBM Holdings Ltd. Corporate Events
HBM Holdings Ltd. announced the grant of share options and share awards to eligible participants under its existing schemes. The grants aim to provide employees with proprietary interests in the company, motivating them to enhance the company’s value. The options have a 10-year exercise period and vest over a period of four years, contingent on performance appraisals. This initiative is expected to align employee interests with those of shareholders, potentially improving the company’s market position.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
HBM Holdings Ltd. announced the successful completion of a share placement, raising funds through the issuance of 45,022,000 new shares at HK$11.50 each, representing 5.17% of the company’s enlarged share capital. The proceeds will be used to enhance research and development, advance clinical activities, upgrade the company’s innovation platform, and support general corporate purposes, positioning the company for growth in the biotechnology sector.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
HBM Holdings Ltd. announced the grant of share options and awards to eligible employees under its existing schemes, aiming to motivate employees and align their interests with company growth. The grants, which are not subject to shareholder approval, include a vesting period tied to performance appraisals, with a clawback mechanism for specific circumstances, reflecting the company’s strategic focus on enhancing shareholder value.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
HBM Holdings Limited, incorporated in the Cayman Islands, has announced a placing of new shares under a general mandate. The company has agreed to place 45,022,000 shares at a price of HK$11.50 per share, which represents various discounts and a slight premium compared to recent trading prices. This move is expected to raise gross proceeds of HK$517.8 million and net proceeds of HK$511.7 million, enhancing the company’s financial position. The placing is subject to certain conditions, and stakeholders are advised to exercise caution as the transaction may or may not proceed.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
HBM Holdings Ltd. reported a significant increase in revenue for the first half of 2025, reaching $101.3 million compared to $23.7 million in the same period of 2024. The company’s profit surged to $73 million from $1.4 million, indicating strong operational performance and financial health. This growth is reflected in the substantial increase in cash and cash equivalents, as well as total assets, positioning HBM Holdings favorably in the market.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
HBM Holdings Limited, a company incorporated in the Cayman Islands, has announced that its Board of Directors will meet on August 27, 2025, to consider and approve the interim results for the first half of 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ perceptions and the company’s market positioning.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
HBM Holdings Ltd. announced that it will present Phase II clinical data for its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, at the ESMO Congress 2025. This presentation will highlight the efficacy and safety of the treatment for microsatellite stable metastatic colorectal cancer, potentially enhancing the company’s position in the oncology market.
HBM Holdings Ltd. has issued a positive profit alert, anticipating a significant profit increase for the first half of 2025, ranging between approximately US$68 million to US$74 million. This growth is primarily driven by strategic collaborations, including a partnership with AstraZeneca, and successful out-licensing and business development activities that have contributed to a stable revenue stream.